These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
4. [Icterus appearing during salvarsan treatment; a case for diagnosis]. VILANOVA X; PINOL Actas Dermosifiliogr; 1949 Nov; 41(2):162. PubMed ID: 15403053 [No Abstract] [Full Text] [Related]
5. [Hypercholesteremic xanthomatosis in intrahepatic obstructive jaundice after administration of salvarsan]. PFEIFFER EF; WIRTZ H Arch Dermatol Syph; 1951; 193(2):99-117. PubMed ID: 14924568 [No Abstract] [Full Text] [Related]
6. [The problem of the so-called salvarsan icterus]. GOTTRON HA Dtsch Z Verdau Stoffwechselkr; 1952; 12(Spec No):77-81. PubMed ID: 12979906 [No Abstract] [Full Text] [Related]
7. [Intrahepatic obstructive jaundice in arsenobenzol therapy]. ELLEGAST H; THALER H Dtsch Med Wochenschr; 1950 Dec; 75(51):1713-5. PubMed ID: 14802150 [No Abstract] [Full Text] [Related]
10. [Use of BAL in diffuse parenchymal disease of the liver]. JANOVICS T; TAKO J Schweiz Med Wochenschr; 1950 Sep; 80(35):933-6. PubMed ID: 15442145 [No Abstract] [Full Text] [Related]
11. [Treatment of salvarsan injury of the liver, with special reference to methionine]. ZIERZ P Arch Dermatol Syph; 1950; 190(5):463-78. PubMed ID: 14777487 [No Abstract] [Full Text] [Related]
12. [The problem of jaundice in antiluetic therapy]. RISSEL E; WEWALKA F Wien Klin Wochenschr; 1952 Feb; 64(8):139-41. PubMed ID: 14922759 [No Abstract] [Full Text] [Related]
13. [Cases of death following salvarsan therapy]. BECKER E Dtsch Med Wochenschr; 1951 Apr; 76(17):572-5. PubMed ID: 14840164 [No Abstract] [Full Text] [Related]